{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:24:49Z","timestamp":1760783089340},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.3816\/clm.2008.s.005","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T01:34:50Z","timestamp":1221528890000},"page":"S95-S106","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S3","title":["Efficacy of Various Doses and Schedules of Second-Generation Tyrosine Kinase Inhibitors"],"prefix":"10.3816","volume":"8","author":[{"given":"Dale L.","family":"Bixby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2008.s.005_bib1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1126\/science.1375394","article-title":"Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro","volume":"256","author":"Gishizky","year":"1992","journal-title":"Science"},{"key":"10.3816\/CLM.2008.s.005_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib3","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","article-title":"In vitro transformation of immature hematopoietic cells by the P210 BCR\/ABL oncogene product of the Philadelphia chromosome","volume":"84","author":"McLaughlin","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2008.s.005_bib4","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.005_bib6","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.005_bib7","first-page":"1661","article-title":"Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)","volume":"4","author":"Beran","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.005_bib8","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2008.s.005_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a Selective Inhibition of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2008.s.005_bib10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.286.8.895","article-title":"Chronic Myelogenous Leukemia","volume":"286","author":"Kalidas","year":"2001","journal-title":"JAMA"},{"key":"10.3816\/CLM.2008.s.005_bib11","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.005_bib12","doi-asserted-by":"crossref","unstructured":"Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Presented at: the American Society of Hematology 46th Annual Meeting and Exposition; December 9\u201312, 2004; Atlanta, GA. Abstract 23.","DOI":"10.1182\/blood.V104.11.23.23"},{"key":"10.3816\/CLM.2008.s.005_bib13","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib16","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI- 571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.3816\/CLM.2008.s.005_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.3816\/CLM.2008.s.005_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib21","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2008.s.005_bib24","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","article-title":"Current and emerging treatment options in chronic myeloid leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.005_bib25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR\u2013ABL inhibitors","volume":"6","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.005_bib26","first-page":"348s","article-title":"Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing BCR-ABL kinase mutations with allogeneic stem cell transplantation (ASCT)","volume":"24","author":"Champlin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.005_bib27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CLM.2008.s.005_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon- \u03b1 therapy","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2008.s.005_bib29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.leu.2402879","article-title":"Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL","volume":"17","author":"Schiffer","year":"2003","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2008.s.005_bib30","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin- 4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2008.s.005_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochem Biophys Acta"},{"key":"10.3816\/CLM.2008.s.005_bib32","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR\u2013ABL kinase inhibitors reveals the role of conformation-specific binding in resistance","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2008.s.005_bib33","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2403775","article-title":"Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies","volume":"19","author":"Gambacorti-Passerini","year":"2005","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2008.s.005_bib34","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2008.s.005_bib35","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome\u2013positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"16 suppl","key":"10.3816\/CLM.2008.s.005_bib36","first-page":"564s","article-title":"A phase I study of BMS- 354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): results from CA180002","volume":"23","author":"Talpaz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.005_bib37","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/sj.leu.2403950","article-title":"Dual tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"19","author":"Martinelli","year":"2005","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2008.s.005_bib38","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2008.s.005_bib39","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","article-title":"Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia","volume":"269","author":"Oda","year":"1994","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2008.s.005_bib40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.leu.2401010","article-title":"Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR\/ABL-transformed cells","volume":"12","author":"Sattler","year":"1998","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2008.s.005_bib41","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.005_bib42","doi-asserted-by":"crossref","first-page":"7023a","DOI":"10.1200\/jco.2007.25.18_suppl.7023","article-title":"Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations","volume":"25","author":"Hochhaus","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.005_bib43","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(87)90754-6","article-title":"Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients","volume":"83","author":"Kantarjian","year":"1987","journal-title":"Am J Med"},{"key":"10.3816\/CLM.2008.s.005_bib45","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1038\/sj.onc.1202619","article-title":"Mutator phenotype of BCRABL transfected Ba\/F3 cell lines and its association with enhanced expression of DNA polymerase beta","volume":"18","author":"Canitrot","year":"1999","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2008.s.005_bib46","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/sj.leu.2401855","article-title":"Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase","volume":"14","author":"Salloukh","year":"2000","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2008.s.005_bib47","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib48","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.005_bib49","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosomepositive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"key":"10.3816\/CLM.2008.s.005_bib51","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase II study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2307\/3577297","article-title":"The effect of low dose rate on recovery of hematopoietic and stromal progenitor cells in \u03b3-irradiated mouse bone marrow","volume":"115","author":"Gallini","year":"1988","journal-title":"Radiat Res"},{"key":"10.3816\/CLM.2008.s.005_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1289\/ehp.898251","article-title":"Long-term hematopoietic damage: concepts, approaches, and results relevant to the study of environmental toxins","volume":"82","author":"Testa","year":"1989","journal-title":"Environ Health Perspec"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.005_bib54","first-page":"358s","article-title":"Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP)","volume":"25","author":"Atallah","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.005_bib55","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian H, Atallah E, et al. Impact of imatinib dose escalation on resistance and suboptimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML). Presented at: the American Society of Hematology 49th Annual Meeting and Exposition; December 8\u201311, 2007; Atlanta, GA. Abstract 1035.","DOI":"10.1182\/blood.V110.11.1035.1035"},{"key":"10.3816\/CLM.2008.s.005_bib56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib57","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib58","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.005_bib59","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of firstline imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS- 354825) is active in Philadelphia chromosome\u2013positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.005_bib61","first-page":"358s","article-title":"Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.005_bib62","first-page":"363s","article-title":"Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: One-year results of CA180-035","volume":"25","author":"Pasquini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.005_bib63","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1\u2013mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib64","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 Activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib65","doi-asserted-by":"crossref","unstructured":"Lee FY, Wen M-L, Bhide R, et al. Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML). Presented at: Presented at: the American Society of Hematology 47th Annual Meeting and Exposition; December 10\u201313,2005; Atlanta, GA. Abstract 1994.","DOI":"10.1182\/blood.V106.11.1994.1994"},{"key":"10.3816\/CLM.2008.s.005_bib66","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib67","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V99.2.664","article-title":"Effects of the Bcr\/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro","volume":"99","author":"Mow","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib68","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.005_bib69","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/cncr.21299","article-title":"AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells","volume":"104","author":"Verstovsek","year":"2005","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.005_bib70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [published erratum in: Cancer Cell 2005; 7:399]","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2008.s.005_bib71","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2008.s.005_bib72","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.005_bib73","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib74","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.2000.18.7.1533","article-title":"Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia","volume":"18","author":"Le Gouill","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.005_bib75","doi-asserted-by":"crossref","first-page":"616a","DOI":"10.1182\/blood.V108.11.2172.2172","article-title":"Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase Inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP)","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.005_bib76","first-page":"363s","article-title":"A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)","volume":"25","author":"le Coutre","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.005_bib77","first-page":"363s","article-title":"A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory Ph+ acute lymphoblastic leukemia (ALL)","volume":"25","author":"Larson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.005_bib78","first-page":"367s","article-title":"A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib","volume":"25","author":"Giles","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.005_bib79","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.005_bib80","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome\u2013 positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.005_bib82","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.005_bib83","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1634\/theoncologist.7-5-390","article-title":"Gleevec\u2122 for the Treatment of Chronic Myelogenous Leukemia: U.S. Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug Status","volume":"7","author":"Cohen","year":"2002","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2008.s.005_bib84","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLM.2008.s.005_bib85","first-page":"653","article-title":"Optimal first-line treatment of chronic myeloid leukemia \u2013 how to use imatinib and what role for newer drugs?","volume":"21","author":"Jabbour","year":"2007","journal-title":"Oncology"},{"key":"10.3816\/CLM.2008.s.005_bib86","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0806-871","article-title":"Bundling next-generation cancer therapies for synergy","volume":"24","author":"Kling","year":"2006","journal-title":"Nat Biotech"},{"key":"10.3816\/CLM.2008.s.005_bib87","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib88","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2007-03-079871","article-title":"Therapeutic drug monitoring in CML patients on imatinib","volume":"110","author":"Blasdel","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib89","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2007-04-087874","article-title":"Use of therapeutic drug monitoring in CML patients on imatinib","volume":"110","author":"Mahon","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib90","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.005_bib91","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.3816\/CLM.2008.s.005_bib92","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T14:00:25Z","timestamp":1631800825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":92,"alternative-id":["S1557919011702700"],"URL":"https:\/\/doi.org\/10.3816\/clm.2008.s.005","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}